Pulmonary Arterial Hypertension Clinical Trial
Official title:
A Multinational, Multicentre, Randomized, Double-blind Study To Assess The Efficacy And Safety Of Oral Sildenafil 20mg Tid Or Placebo When Added To Bosentan In The Treatment Of Subjects, Aged 18 Years And Above, With Pulmonary Arterial Hypertension (Pah)
Verified date | January 2021 |
Source | Pfizer |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
To assess the efficacy and safety of sildenafil when added to patients with PAH who are taking bosentan as all or part of their background therapy.
Status | Completed |
Enrollment | 105 |
Est. completion date | August 2013 |
Est. primary completion date | August 2013 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Subjects aged 18 and over above with PAH and for which bosentan therapy is indicated according to national license - Subjects with a mean pulmonary artery pressure of >25mmHg and a pulmonary artery wedge pressure of <15mmHg at rest via right heart catheterization within 3 years prior to randomization. - Subjects whose baseline 6 Minute Walk Test distance is >100m and < 450m. Exclusion Criteria: - PAH secondary to any aetiology including congenital heart disease other than those specified in the inclusion criteria - Subjects whose 6 Minute Walk Test may be limited by conditions other than PAH related dyspnoea or fatigue eg. claudication from vascular insufficiency or arthritis. |
Country | Name | City | State |
---|---|---|---|
Australia | The Prince Charles Hospital | Chermside | Queensland |
Australia | St. Vincents Hospital | Darlinghurst | New South Wales |
Czechia | Vseobecna fakultni nemocnice v Praze | Praha 2 | |
Czechia | Institut klinicke a experimentalni mediciny, Klinika kardiologie | Praha 4 | |
France | Clinique des Maladies Respiratoires | Lille | |
France | Hopital Claude Huriez | Lille | |
France | Hopital Adules Brabois | Vandoeuvre Les Nancy | |
Germany | Unfallkrankenhaus Berlin, Klinik fuer Innere Medizin | Berlin | |
Germany | II. Medizinische Klinik, Kardiologie, Angiologie und Pneumologie | Coburg | |
Germany | Universitaetsklinikum Essen, Zentrum fuer Innere Medizin, Klinik fuer Kardiologie | Essen | |
Germany | Universitaetsklinikum Giessen und Marburg GmbH, Standort Giessen | Giessen | |
Germany | Medizinische Hochschule Hannover | Hannover | |
Germany | Universitaetsklinikum des Saarlandes, Innere Medizin V | Homburg | |
Germany | Medizinische Klinik und Poliklinik I, Universitaetsklinikum Leipzig | Leipzig | |
Germany | Med. Klinik u. Poliklinik I der LMU Muenchen, Klinikum Grosshadern | Muenchen | |
Germany | Praxis fuer Innere Medizin, Kardiologie und Angiologie | Nuernberg | |
Germany | Missionsaerztliche Klinik Wuerzburg, Gemeinnuetzige Gesellschaft mbH | Wuerzburg | |
Greece | Attikon Hospital | Haidari | Athens |
Israel | Rambam Medical Center | Haifa | |
Israel | Rabin Medical Centre | Petach Tikva | |
Italy | Cardiologia, Azienda Ospedaliera Monaldi, Seconda Università di Napoli | Napoli | |
Italy | Unita' di Ipertensione Polmonare, Dipartimento di Scienze Respiratorie e Cardiovascolari | Roma | |
Taiwan | Department of Surgery, National Taiwan University Hospital | Taipei | |
United Kingdom | PVDU | Papworth Everard | Cambridgeshire |
United States | Henry Ford Hospital | Detroit | Michigan |
United States | Baylor College of Medicine | Houston | Texas |
United States | The Methodist Hospital | Houston | Texas |
United States | West Los Angeles VA Healthcare, Pulmonary Hypertension Program | Los Angeles | California |
United States | Allegheny General Hospital | Pittsburgh | Pennsylvania |
United States | Diagnostics Research Group | San Antonio | Texas |
Lead Sponsor | Collaborator |
---|---|
Pfizer's Upjohn has merged with Mylan to form Viatris Inc. |
United States, Australia, Czechia, France, Germany, Greece, Israel, Italy, Taiwan, United Kingdom,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change From Baseline in the Total Distance Walked During 6 Minute Walk Time (6MWT) at Week 12 | 6MWT is the distance that a participant could walk in 6 minutes. Participants were asked to perform the test at a pace that was comfortable to them, with as many breaks as they needed. Continuous pulse oximetry was conducted during the test for safety. | Week 12 | |
Secondary | Number of Participants With Change From Baseline in World Health Organization (WHO) Functional Class in Participants With PAH at Week 12 LOCF | WHO functional classification for PAH range from Class I (no limitation in physical activity, no dyspnea with normal activity) to Class IV (can not perform a physical activity without any symptoms, dyspnea at rest). Improvement=reduction in functional class; deterioration = increase in functional class, no change = no change in functional class. | Week 12 | |
Secondary | Clinical Worsening Events | No survival analysis was carried out for the study due to very few events of clinical worsening. Hence, we present a summary of clinical worsening events instead. Events of clinical worsening were categorized as (A). Death, (B). Heart/lung transplantation, (C). Hospitalization due to pulmonary arterial hypertension (PAH), and (D). Clinical deterioration of PAH requiring additional therapy. |
Week 12 | |
Secondary | Change From Baseline in Borg Dyspnea Score at Week 12 | Borg dyspnea scale is a 10-point scale where following scores stands for severity of dyspnea: 0 (no breathlessness at all); 0.5 (very very slight [just noticeable]); (very slight); (slight breathlessness); (moderate); 4 (some what severe); 5 (severe breathlessness); 7 (very severe breathlessness); 9 (very very severe [almost maximum]); and 10 (maximum). |
Week 12 | |
Secondary | One Year Survival Probability From the Start of Sildenafil Treatment. | The survival probability of all participants up to 1-year post start of Sildenafil treatment; for participants who were randomized to Sildenafil, this was the week 52 from randomization, and for participants who were originally randomized to Placebo group, this was the Week 64 from Baseline (Week 52 from Week 12, when the first dose of Sildenafil was administered to these participants). Those participants who discontinued from the study prior to 1 year after start of sildenafil were considered as censored at the time of discontinuation and those who discontinued from the study post 1-year after start of sildenafil were considered as censored at the time of 1-year post start of sildenafil. | One year from the time of starting sildenafil | |
Secondary | One Year Survival From the Start of Sildenafil Treatment. | The survival status of all participants who discontinued from the study, including those participants who discontinued during the double-blind phase, was to be assessed at one year post their Week 12 visit/ End of treatment visit. | One year from the time of starting sildenafil |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04076241 -
Effects of Adding Yoga Respiratory Training to Osteopathic Manipulative Treatment in Pulmonary Arterial Hypertension
|
N/A | |
Completed |
NCT05521113 -
Home-based Pulmonary Rehabilitation With Remote Monitoring in Pulmonary Arterial Hypertension
|
||
Recruiting |
NCT04972656 -
Treatment With Ambrisentan in Patients With Borderline Pulmonary Arterial Hypertension
|
N/A | |
Completed |
NCT04908397 -
Carnitine Consumption and Augmentation in Pulmonary Arterial Hypertension
|
Phase 1 | |
Active, not recruiting |
NCT03288025 -
Pulmonary Arterial Hypertension Improvement With Nutrition and Exercise (PHINE)
|
N/A | |
Completed |
NCT01959815 -
Novel Screening Strategies for Scleroderma PAH
|
||
Recruiting |
NCT04266197 -
Vardenafil Inhaled for Pulmonary Arterial Hypertension PRN Phase 2B Study
|
Phase 2 | |
Active, not recruiting |
NCT06092424 -
High Altitude (HA) Residents With Pulmonary Vascular Diseseases (PVD), Pulmonary Artery Pressure (PAP) Assessed at HA (2840m) vs Sea Level (LA)
|
N/A | |
Enrolling by invitation |
NCT03683186 -
A Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Extension
|
Phase 3 | |
Terminated |
NCT02060487 -
Effects of Oral Sildenafil on Mortality in Adults With PAH
|
Phase 4 | |
Terminated |
NCT02253394 -
The Combination Ambrisentan Plus Spironolactone in Pulmonary Arterial Hypertension Study
|
Phase 4 | |
Withdrawn |
NCT02958358 -
FDG Uptake and Lung Blood Flow in PAH Before and After Treatment With Ambrisentan
|
N/A | |
Terminated |
NCT01953965 -
Look at Way the Heart Functions in People With Pulmonary Hypertension (PH) Who Have Near Normal Right Ventricle (RV) Function and People With Pulmonary Hypertension Who Have Impaired RV Function. Using Imaging Studies PET Scan and Cardiac MRI.
|
Phase 2 | |
Not yet recruiting |
NCT01649739 -
Vardenafil as add-on Therapy for Patients With Pulmonary Hypertension Treated With Inhaled Iloprost
|
Phase 4 | |
Unknown status |
NCT01712997 -
Study of the Initial Combination of Bosentan With Iloprost in the Treatment of Pulmonary Hypertension Patients
|
Phase 3 | |
Withdrawn |
NCT01723371 -
Beta Blockers for Treatment of Pulmonary Arterial Hypertension in Children
|
Phase 1/Phase 2 | |
Completed |
NCT01548950 -
Drug Therapy and Surgery in Congenital Heart Disease With Pulmonary Hypertension
|
N/A | |
Completed |
NCT01165047 -
Nitric Oxide, GeNO Nitrosyl Delivery System
|
Phase 2 | |
Completed |
NCT00963001 -
Effect of Food on the Pharmacokinetics of Oral Treprostinil
|
Phase 1 | |
Completed |
NCT00963027 -
Effect of Esomeprazole on the Pharmacokinetics of Oral Treprostinil
|
Phase 1 |